iRhythm Technologies (NASDAQ:IRTC), Inc. is a commercial-stage digital health company specializing in the detection and management of cardiac arrhythmias. The company’s flagship offering, the Zio portfolio, combines a wearable, single-use patch with cloud-based analytical tools to provide continuous electrocardiogram (ECG) monitoring for patients suspected of having irregular heart rhythms. By capturing and transmitting high-resolution cardiac data over multiple days, iRhythm’s platform enables clinicians to diagnose and treat conditions such as atrial fibrillation, bradycardia and supraventricular tachycardia with greater accuracy than traditional Holter monitors.
At the core of iRhythm’s service is its proprietary machine-learning algorithm, which automatically identifies and classifies arrhythmic events. Data collected from the Zio patch are securely uploaded to the company’s Zio AT (Arrhythmia Technology) analytics engine, where advanced signal processing and pattern recognition software generate detailed reports for physicians. This end-to-end solution streamlines the diagnostic workflow, reduces manual review time and supports evidence-based clinical decision-making.
Founded in 2006 and headquartered in San Francisco, California, iRhythm has expanded its reach across the United States and into select international markets. Since its initial public offering in 2016, the company has formed partnerships with major health systems, cardiology practices and telehealth providers to integrate its ambulatory monitoring services into broader patient care pathways. Through ongoing investments in research and development, iRhythm continues to refine its wearable technology and analytic capabilities, with a focus on improving patient outcomes and reducing the burden of undiagnosed arrhythmias.
iRhythm’s leadership team is led by Chief Executive Officer Kevin King, who brings extensive experience in commercializing medical devices and scaling global healthcare businesses. The company’s management group also includes seasoned executives in clinical operations, regulatory affairs and data science, reflecting iRhythm’s commitment to innovation and quality. Under this guidance, the company pursues strategic collaborations, publishes clinical evidence and advocates for value-based care models that recognize the long-term benefits of early arrhythmia detection.
